Leap therapeutics announces completion of enrollment in part b of the defiance study of dkn-01 for the treatment of colorectal cancer patients

Cambridge, mass. , sept. 30, 2024 /prnewswire/ -- leap therapeutics, inc. (nasdaq: lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled part b of the defiance study evaluating dkn-01, leap's anti-dickkopf-1 (dkk1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (crc).
LPTX Ratings Summary
LPTX Quant Ranking